A Phase 3 interventional study of Methylprednisolone sodium succinate and Placebo in Acute Ischemic Stroke and Large Infarct Core, sponsored by Wan-Jin Chen. Active, not recruiting at 99 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-03.
Sponsored by Wan-Jin Chen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 754 studies in Ischemic Stroke with a site in China — 381 open to participants now, 400 under way, 78 of them phase 3. Ischemic Stroke · China.
Among the 754 studies in Ischemic Stroke with a site in China, this one is the 116th largest by enrollment of the 566 interventional ones that give a count, is one of 103 that started in 2024, is one of 111 in phase 3, reaches primary completion later than 62 of the 399 other live ones, and was the 451st registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →381 of the 754 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:
Xidian University · Sites in China
Ages 18+
The First Affiliated Hospital of Zhengzhou University · Sites in China
Ages 18+
Shanghai Jiao Tong University Affiliated Sixth People's Hospital · Sites in China
Ages 18–85
Yongjun Wang · Sites in China
Ages 18+
Shandong Provincial Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
754 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 42 · Phase 2 110 · Phase 3 136 · Phase 4 70
First in 2000; this study’s year is marked. 103 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 928 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 271 across the 566 interventional studies, 625 across the 188 observational. Of the 235 that completed or were terminated, 11 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 754 have an industry lead sponsor. The 10 most frequent:
Wan-Jin Chen is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Wan-Jin Chen has 1 study filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
108 of the studies in Ischemic Stroke with a site in China that are under way reach primary completion within a year, 22 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559241Phase 3Capital Medical UniversityRemote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical Thrombectomy(RECAST-MT) | 2026-11 |
| NCT06658197Phase 3Xuanwu Hospital, BeijingEfficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke | 2026-12-01 |
| NCT06749834Phase 3Second Affiliated Hospital, School of Medicine, Zhejiang UniversityIntravenous Thrombolysis and NOAC | 2026-12-31 |
| NCT07335107Phase 3Beijing Tiantan HospitalIntravenous Tirofiban After Bridging Therapy for Acute Stroke With Atherosclerotic Large Artery Occlusion | 2027-01-31 |
| NCT06954155Phase 3Beijing Tiantan HospitalTenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND | 2027-02-28 |
Add all 108 to your calendar (.ics) → With an account.
Among the 754 studies in Ischemic Stroke with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The efficacy and safety of methylprednisolone in acute ischemic stroke patients with large infarct cores (ASPECTS score \< 6 or infarct volume ≥50 mL) due to anterior circulation large vessel occlusion have not been clearly established. This is a multi-center, randomized, double-blind, placebo-controlled trial to investigate early combination therapy with methylprednisolone for reperfusion in acute large core infarction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Methylprednisolone sodium succinate simulant
Drug: Placebo
Intravenous injection of methylprednisolone sodium succinate (Chongqing Lummy Pharmaceutical Co., Ltd., 40mg/bottle) with a dose of 2mg/kg (maximum dose of 160mg), once daily, for three consecutive days. The initial study drug will be administered as soon as possible after randomization. It is recommended that the initial study drug administrated before arterial access closure, but it should not be delayed more than 2 hours after arterial access closure.
Intravenous injection of placebo (Chongqing Lummy Pharmaceutical Co., Ltd., 40mg/bottle) with a dose of 2mg/kg (maximum dose of 160mg), once daily, for three consecutive days. The initial study drug will be administered as soon as possible after randomization. It is recommended that the initial study drug administrated before arterial access closure, but it should not be delayed more than 2 hours after arterial access closure.
All-cause mortality at 90 (±14) days
Primary Efficacy Outcome. Defined as the number of any cause deaths observed divided by the number of subjects observed over the 90-day study period.
Time frame: From randomization to 90 (±14) days
Time from randomization to the occurrence of death from any cause at 90 (±14) days
Secondary Efficacy Outcome; To evaluate death rate of the two treatment groups
Time frame: From randomization to 90 (±14) days
mRS ordinal shift at 90 (±14) days (scores 5 and 6 are merged)
Secondary Efficacy Outcome
Time frame: From randomization to 90 (±14) days
Proportion of patients with mRS score 0 to 4 at 90 (±14) days
Secondary Efficacy Outcome
Time frame: From randomization to 90 (±14) days
Proportion of patients with mRS score 0 to 3 at 90 (±14) days
Secondary Efficacy Outcome
Time frame: From randomization to 90 (±14) days
Proportion of patients with mRS score 0 to 2 at 90 (±14) days
Secondary Efficacy Outcome
Time frame: From randomization to 90 (±14) days
Proportion of patients with mRS score 0 to 1 at 90 (±14) days or return to pre-stroke mRS score (for patients with pre-stroke mRS > 1)
Secondary Efficacy Outcome
Time frame: From randomization to 90 (±14) days
Midline shift at 48 hours
Secondary Efficacy Outcome
Time frame: From randomization to 48 hours
Proportion of patients with midline shift >5 mm within 48 hours after EVT
Secondary Efficacy Outcome
Time frame: From randomization to 48 hours
Relative hemispheric volume at 48 hours
Secondary Efficacy Outcome.
Time frame: From randomization to 48 hours
Net water uptake at 48 hours
Secondary Efficacy Outcome
Time frame: From randomization to 48 hours
Proportion of patients with decompressive craniectomy after EVT
Secondary Efficacy Outcome
Time frame: From randomization until the date of discharge, an average of 1 week
NIHSS score at 5-7 days or at early discharge
Secondary Efficacy Outcome
Time frame: From randomization to 5-7 days ( or at early discharge)
EQ-5D-5L VAS at 90 (±14) days
Secondary Efficacy Outcome
Time frame: From randomization to 90 (±14) days
Proportion of patients with symptomatic intracranial haemorrhage (SICH) within 48 hours after EVT
Primary Safety Outcome. Based on the modified Heidelberg Bleeding Classification.
Time frame: From randomization to 48 hours
Proportion of patients with any intracranial haemorrhage (ICH) within 48 hours after EVT
Secondary Safety Outcome. Based on the modified Heidelberg Bleeding Classification.
Time frame: From randomization to 48 hours
Proportion of patients with pneumonia
Secondary Safety Outcome
Time frame: From randomization until the date of discharge, an average of 1 week
Proportion of patients with gastrointestinal haemorrhage within 7 days after EVT
Secondary Safety Outcome
Time frame: From randomization to 7 days
Incidence of any complications
Secondary Safety Outcome
Time frame: From date of randomization until the date of discharge, an average of 1 week
Incidence of any (serious) adverse events
Secondary Safety Outcome
Time frame: From randomization to 90 (±14) days
mRS ordinal shift at 1 year (scores 5 and 6 are merged)
Tertiary Efficacy Outcome
Time frame: From randomization to 1 year
Proportion of patients with mRS score 0 to 2 at 1 year
Tertiary Efficacy Outcome
Time frame: From randomization to 1 year
Proportion of patients with mRS score 0 to 1 at 1 year or return to pre-stroke mRS score (for patients with pre-stroke mRS > 1)
Tertiary Efficacy Outcome
Time frame: From randomization to 1 year
mRS ordinal shift at 5 years (scores 5 and 6 are merged)
Tertiary Efficacy Outcome
Time frame: From randomization to 5 years
Proportion of patients with mRS score 0 to 2 at 5 years
Tertiary Efficacy Outcome
Time frame: From randomization to 5 years
Proportion of patients with mRS score 0 to 1 at 5 years or return to pre-stroke mRS score (for patients with pre-stroke mRS > 1)
Tertiary Efficacy Outcome
Time frame: From randomization to 5 years
EQ-5D-5L VAS at 1 year
Tertiary Efficacy Outcome
Time frame: From randomization to 1 year
EQ-5D-5L VAS at 5 years
Tertiary Efficacy Outcome
Time frame: From randomization to 5 years
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2024 to primary completion in Sep 2025, 13 months.
Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 13 months is below that.
Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methylprednisolone Hemisuccinate